Nxstage Medical Earnings Up Next
Nxstage Medical (NAS: NXTM) is expected to report Q2 earnings on Aug. 8. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nxstage Medical's revenues will improve 8.0% and EPS will remain in the red.
The average estimate for revenue is $58.1 million. On the bottom line, the average EPS estimate is -$0.09.
Last quarter, Nxstage Medical booked revenue of $57.0 million. GAAP reported sales were 13% higher than the prior-year quarter's $50.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.09. GAAP EPS were -$0.09 for Q1 against -$0.11 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 37.4%, 170 basis points better than the prior-year quarter. Operating margin was -6.4%, 280 basis points better than the prior-year quarter. Net margin was -9.0%, 290 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $241.6 million. The average EPS estimate is -$0.28.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 136 members out of 169 rating the stock outperform, and 33 members rating it underperform. Among 48 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 36 give Nxstage Medical a green thumbs-up, and 12 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nxstage Medical is outperform, with an average price target of $26.00.
- Add Nxstage Medical to My Watchlist.
The article Nxstage Medical Earnings Up Next originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend NxStage Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.